Effects of Rimonabant on Cannabinoid Receptor 1 andα-Smooth Muscle Actin in C57 Mice with Experimental Hepatic Fibrosis
10.3969/j.issn.0253-9896.2014.05.011
- VernacularTitle:利莫那班对肝纤维化C57小鼠肝组织大麻素受体1及α-SMA表达的影响
- Author:
Lihong YE
;
Chongkui WANG
;
Xiuli CHEN
;
Li YANG
;
Erhei DAI
- Publication Type:Journal Article
- Keywords:
receptor,cannabinoid,CB1;
liver cirrhosis;
actins;
mice,inbred C57BL;
RIMONABANT;
α-smooth muscle actin;
cannabinoid receptor 1
- From:
Tianjin Medical Journal
2014;(5):440-442
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of rimonabant, cannabinoid receptor 1(CB1) antagonist, on the expressions of CB1 andα-smooth muscle actin (α-SMA) in C57 mice with experimental hepatic fibrosis, and their mechanisms in liver fibrosis progression thereof. Methods Thirty C57 mice were randomly divided into three groups, normal control group, mod-el control group and model+rimonabant group, 10 mice for each group. The mouse model of experimental hepatic fibrosis was induced by intraperitoneal injection with 10%CCl4 for two weeks. The normal saline was delivered by gavage daily in normal control group and model control group. Rimonabant was given to mice in model+rimonabant group. Mice were sacri-ficed at the end of eight weeks. Samples of liver tissue were collected. The expressions of CB1 andα-SMA in liver tissue of mice were observed by immunohistochemical staining. The score of fibrosis stage (S) in liver tissue was also analyzed. Re-sults The positive expressions of CB1 andα-SMA and the score S were significantly higher in model control group and model+rimonabant group than those in normal control group (P<0.05). The positive expressions of CB1 andα-SMA and the score S were significantly lower in rimonabant group than those in model control group (P<0.05). There were positive corre-lations in CB1,α-SMA and S scores between normal control group, model control group and model+rimonabant group (P<0.05). Conclusion The activation of CB1 can promote the formation of liver fibrosis. The anti-fibrotic effect of rimonabant, CB1 antagonist, related with the inhibiting of the proliferation and activation of hepatic stellate cells (HSC), and the inhibit-ing of the expression of CB1.
